Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy Virtual 2020 | Graham Jackson: COMy 2020 rundown

Graham Jackson • 16 May 2020
COMy Virtual 2020
Multiple Myeloma Rare Diseases Smoldering Myeloma

Graham Jackson, MBBS, FRCP, FRCPath, MD, Newcastle upon Tyne Hospitals NHS Trust, Newcastle, UK, provides an overview of the COMy 2020 virtual meeting, discussing the key issues debated and questions raised. Specifically discussed is smoldering myeloma, high-risk disease and disease burden. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Graham Jackson

Myeloma treatment updates: a UK perspective
Graham Jackson et al. • 14 Jun 2022
The management of patients with lenalidomide-refractory multiple myeloma in the UK 1:00
The management of patients with lenalidomide-refractory multiple myeloma in the UK
Graham Jackson • 30 Jan 2025
Recent approvals and updates impacting myeloma treatment in the UK 1:45
Recent approvals and updates impacting myeloma treatment in the UK
Graham Jackson • 30 Jan 2025
Unmet needs that remain for patients with myeloma in the UK 1:19
Unmet needs that remain for patients with myeloma in the UK
Graham Jackson • 30 Jan 2025

Related Videos

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals